8-K: Inotiv Reports Weak Second Quarter Results and Reaches Agreement in Principle with DOJ

Inotiv's second quarter fiscal 2024 revenue declined by 21.5% year-over-year, with a significant drop in Research Models and Services revenue, and the company reached an agreement in principle with the U.S. Department of Justice.

Summary

• Inotiv's revenue for the second quarter of fiscal year 2024 was $119.0 million, a 21.5% decrease compared to $151.5 million in the same period last year.
• The decline was primarily driven by a 30.7% decrease in Research Models and Services (RMS) revenue, which fell by $32.1 million.
• Year-to-date revenue for fiscal year 2024 was $254.5 million, a 7.2% decrease compared to $274.2 million in the same period last year.
• The company reported a net loss of $48.1 million for the quarter, compared to a net loss of $9.6 million in the prior year, which includes a $26.5 million charge related to an agreement in principle with the Department of Justice.
• Adjusted EBITDA for the quarter was $3.1 million, down from $17.1 million in the same quarter last year.
• The book-to-bill ratio for the Discovery and Safety Assessment (DSA) services business was 0.77x for the quarter.
• The company has accrued an estimate of $26.5 million related to the agreement in principle with the DOJ, with additional cash outlays expected over the next three to five years.
• The company has withdrawn its financial guidance for fiscal year 2024 due to uncertainty in customer demand for non-human primates (NHPs).

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to significant revenue decline, a large net loss, decreased EBITDA, and the withdrawal of financial guidance. The agreement in principle with the DOJ and associated costs further contribute to the negative sentiment.

Positives

• The company completed the in-house integration of its North American transportation operations, which is expected to lead to further efficiencies and cost reductions.
• Expansion activities at the Fort Collins, CO, site were completed and the site became operational in the second quarter of fiscal 2024.
• The company is progressing with its site optimization plan, including the relocation of operations from Blackthorn to Hillcrest, U.K., expected to be completed by the end of September 2024.
• Cash provided by operating activities was $10.4 million for YTD FY 2024, compared to $5.4 million for YTD FY 2023.
• The company was in compliance with its debt covenants as of March 31, 2024.

Negatives

• Second quarter revenue decreased by 21.5% year-over-year, primarily due to a significant decline in RMS revenue.
• The company reported a net loss of $48.1 million for the quarter, compared to a net loss of $9.6 million in the same period last year.
• Adjusted EBITDA decreased significantly to $3.1 million from $17.1 million in the prior year's second quarter.
• The book-to-bill ratio for the DSA services business was below 1x at 0.77x, indicating a potential slowdown in future revenue.
• The company has accrued a $26.5 million charge related to the agreement in principle with the DOJ, with additional cash outlays expected over the next three to five years.
• The company withdrew its financial guidance for fiscal year 2024 due to uncertainty in NHP demand.
• The company's DSA backlog decreased to $142.1 million at March 31, 2024, down from $152.3 million at December 31, 2023.

Risks

• The company faces uncertainty in customer demand for non-human primates (NHPs), which significantly impacts consolidated revenue and margins.
• The agreement in principle with the DOJ is subject to material contingencies, and there is no assurance that a final resolution will be agreed and finalized.
• The company expects additional cash outlays related to the DOJ agreement over the next three to five years, which could impact its financial position.
• The company's debt is classified as current on the balance sheet due to the potential for failure to comply with financial covenants.
• The company's restructuring and site optimization plans may not achieve the expected benefits.
• The company's ability to service its outstanding indebtedness and comply with financial covenants is a risk.
• The company's ability to manage recurring and unusual costs is a risk.

Future Outlook

The company has withdrawn its financial guidance for fiscal year 2024 due to uncertainty in customer demand for non-human primates. The company remains focused on executing its long-term strategic plan, including optimizing market share in the DSA segment and increasing sales efforts.

Management Comments

• Robert Leasure Jr., President and Chief Executive Officer, commented that revenue in this reporting period was less than expected due to weak NHP demand and a decrease in early-stage discovery work.
• Management stated that the transformation of Inotiv's business is supported by a reduction in expenses while ramping sales and marketing efforts to grow revenue and margins.
• Management noted that they have further reduced their workforce and other expenses as they improved efficiencies and moved to right size their operations.

Industry Context

The contract research organization (CRO) industry is facing challenges related to fluctuating demand for specific services, particularly non-human primates. Inotiv's results reflect these broader industry trends, highlighting the need for CROs to diversify their service offerings and manage costs effectively. The agreement in principle with the DOJ also underscores the regulatory scrutiny that CROs face.

Comparison to Industry Standards

• Inotiv's 21.5% revenue decrease in Q2 FY24 is significantly worse than the performance of some of its peers in the CRO industry. For example, Charles River Laboratories (CRL) reported a 1.7% revenue increase in their most recent quarter, while Labcorp (LH) reported a 3.8% increase in their most recent quarter.
• The decline in Inotiv's RMS segment revenue by 30.7% is a major concern, as this segment is a significant contributor to their overall revenue. Other CROs with similar research model offerings have not reported such a steep decline, suggesting company-specific issues.
• Inotiv's adjusted EBITDA margin of 2.6% in Q2 FY24 is significantly lower than the industry average. For example, Charles River Laboratories reported an adjusted operating margin of 18.5% in their most recent quarter, and Labcorp reported an adjusted operating margin of 13.5%.
• The book-to-bill ratio of 0.77x for Inotiv's DSA services business indicates a potential slowdown in future revenue, as it suggests that the company is not securing enough new contracts to replace the revenue from completed projects. This is below the industry average of around 1.0x.
• The $26.5 million charge related to the DOJ agreement in principle is a significant one-time expense that has negatively impacted Inotiv's profitability. While other CROs may face regulatory issues, the magnitude of this charge is unusual and suggests a more serious underlying problem.

Corporate Governance

Legal Proceedings

• The company has reached an agreement in principle with the U.S. Department of Justice (DOJ) to resolve an investigation related to a search and seizure warrant executed on the Cumberland facility in 2022.
• The agreement in principle is subject to material contingencies, including negotiations and final approvals.

Stakeholder Impact

• Shareholders are negatively impacted by the significant revenue decline, net loss, and withdrawal of financial guidance.
• Employees may be impacted by the ongoing restructuring and workforce reductions.
• Customers may be impacted by the uncertainty surrounding the company's financial performance and the DOJ investigation.
• Creditors may be concerned about the company's ability to service its debt and comply with financial covenants.

Next Steps

• The company will continue to execute its site optimization plan, including the relocation of operations from Blackthorn to Hillcrest, U.K.
• The company will focus on optimizing market share and increasing awards in the DSA segment.
• The company will continue to work towards a final resolution with the U.S. Department of Justice.
• The company will continue to focus on client satisfaction through innovation and the development of nimble solutions and custom offerings.

Key Dates

Keywords

Inotiv, contract research organization, nonclinical, drug discovery, research models, financial results, revenue, EBITDA, Department of Justice, NHP, site optimization, book-to-bill, backlog